Mukka Proteins to acquire 2,000 shares of Haris Marine Products for ₹19.64 Lakh, making it wholly owned subsidiary
Mukka Proteins will acquire 2,000 equity shares of Haris Marine Products Private Limited for ₹19.64 Lakh, making it a wholly owned subsidiary. The acquisition is targeted for completion by June 30, 2026, and is a strategic move to expand the company's core business. HMPPL is a manufacturer and exporter of fish meal and fish oil.
The acquisition is of a subsidiary and aims to make it wholly owned, which is a strategic expansion but the financial value is relatively small in the context of a listed company.
The acquisition is a strategic move to increase the company's stake in its subsidiary and expand its core business, which is viewed positively.
Mukka Proteins Limited announced on February 12, 2026, that its Board of Directors has approved the further acquisition of 2,000 equity shares, each with a face value of ₹100, of its subsidiary, Haris Marine Products Private Limited (HMPPL). The total consideration for this acquisition from existing shareholders is ₹19,64,000 (Nineteen Lakhs Sixty-Four Thousand Rupees).
Upon completion of this investment, HMPPL will become a wholly owned subsidiary of Mukka Proteins Limited, increasing the company's shareholding in HMPPL from 98% to 100%. The acquisition is part of the company's strategic investment plans to expand its core business. HMPPL is engaged in the manufacturing and export of fish meal and fish oil. The indicative time period for the completion of this acquisition is June 30, 2026. The transaction is an arm's length transaction, although HMPPL is considered a related party as it is a subsidiary.
HMPPL has an authorized and paid-up capital of ₹1,00,00,000. For the financial year 2024-25, HMPPL reported a turnover of Nil and a Profit After Tax (PAT) of ₹2,24,01,700. The turnover for FY 2023-24 was also Nil. However, for the financial year ending March 2023, HMPPL reported a turnover of ₹50,95,31,673. The meeting of the Board of Directors commenced at 4:00 p.m. and concluded at 4:45 p.m.
What to do with a filing like this
Mukka Proteins Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mukka Proteins Limited. Read the original for the full detail.